Douglas M. Lankler - 26 Feb 2022 Form 4 Insider Report for PFIZER INC (PFE)

Role: Executive Vice President
Signature: Susan E. Grant, by power of atty., for Douglas M. Lankler
Issuer symbol: PFE
Transactions as of: 26 Feb 2022
Net transactions value: -$857,200
Form type: 4
Filing time: 01 Mar 2022, 15:03:11 UTC
Previous filing: 25 Feb 2022
Next filing: 13 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PFE	Common Stock	Options Exercise	$1,989,350	+77,709	+80%	$25.60	174,507	26 Feb 2022	Direct	F1
transaction	PFE	Common Stock	Tax liability	$1,009,230	-21,149	-12%	$47.72	153,358	26 Feb 2022	Direct	F2, F3
transaction	PFE	Common Stock	Tax liability	$1,837,320	-36,282	-24%	$50.64	117,076	26 Feb 2022	Direct	F4, F5
holding	PFE	Common Stock						1,681	26 Feb 2022	By Rule 16b-3 Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PFE	Stock Appreciation Rights	Options Exercise	$0	-77,709	-100%	$0.000000^*	0	26 Feb 2022	Common Stock	77,709	$25.60	Direct
transaction	PFE	Stock Appreciation Rights	Award	$0	+10,566		$0.000000	10,566	28 Feb 2022	Common Stock	10,566	$46.94	Direct	F6
transaction	PFE	Stock Appreciation Rights	Award	$0	+9,294		$0.000000	9,294	28 Feb 2022	Common Stock	9,294	$46.94	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2	The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3	Price is the closing price of Pfizer common stock on February 25, 2022.
F4	The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F5	Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
F6	The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
F7	The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.